9 results about "Neuronal regeneration" patented technology

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

The invention discloses injectable hydrogel and a preparation method and application thereof in nerve repair, the hydrogel is medical hydrogel of poly-beta amino ester loaded with indole-3-propionic acid, and the hydrogel comprises the following raw materials: polyethylene glycol diacrylate (PEGDA) as a scaffold material; a molecule containing a double primary amine group as a cross-linking agent, the cross-linking agent being cross-linked with polyethylene glycol diacrylate (PEGDA) via an acrylate bond; and indole-3-propionic acid (IPA) as an active ingredient. The injectable hydrogel is adjustable in mechanical property and excellent in biocompatibility, can slowly release IPA, and is used for filling nerve injury areas, inhibiting oxidative stress and promoting neuron regeneration and functional recovery.

A composition and method for transdifferentiating non-neuronal cells into neurons. Disclosed is a composition for inducing cell transdifferentiation, comprising a Myosin inhibitor, and an isoxazole compound and / or its derivatives. Also disclosed is a method for inducing non-neuronal cells to transdifferentiate into neurons, comprising: culturing non-neuronal cells in an induction culture medium comprising a Myosin inhibitor, and then culturing them in a maturation culture medium comprising a Myosin inhibitor and an isoxazole compound and / or its derivatives until mature neurons are obtained. Also disclosed is a use of the composition in inducing non-neuronal cells to transdifferentiate into neurons, and a method for transdifferentiating non-neuronal cells in a subject into neurons, comprising administering an effective amount of a Myosin inhibitor and an isoxazole compound and / or its derivatives to the subject. The method of the present application is simple, requiring only two simple small molecule combination treatments, without the need for regulation by overexpression of specific genes, and can be performed efficiently both in vivo and in vitro, thereby achieving simple and efficient neuronal regeneration.

In one aspect, the present disclosure provides nano and microstructures of conducting polymers which may be used in the treatment of neuron regeneration. In some embodiments, the microstructures may be a microcup or a nanogroove structure. The present disclosure also provides methods of preparing the conducting polymer coated microstructures and methods of using these compositions or structures.

The present disclosure provides new and innovative compositions of Neuronal regeneration-promoting cells (NRPCs), methods for generating NRPCs, and methods of treating subjects having damaged nerve cells using NRPCs. In an embodiment, the NRPCs are induced from tonsil-derived mesenchymal stem cells and express CD26, CD106, CD112, CD121a, and CD141, wherein CD121a has an expression level of about 30% or higher, the expression level measured immediately after thawing the NRPCs from a frozen state. Furthermore, the NRPCs are configured to promote formation of axons on neuronal cells.

The present disclosure provides novel and innovative compositions of neuronal regeneration promoting cells (NRPCs), methods for producing NRPCs, and methods of treating subjects having impaired nerve cells using NRPCs. In one embodiment, the NRPC is induced by a tonsil-derived mesenchymal stem cell and expresses CD26, CD106, CD112, CD121a, and CD141, where CD121a has an expression level of about 30% or more, which is measured immediately after the NRPC has been thawed from a frozen state. In addition, the NRPC is configured to promote the formation of axons on neuronal cells.

The present application belongs to the technical field of biological materials, and particularly relates to a microemulsion hydrogel as well as a preparation method and application thereof. The microemulsion hydrogel has a network structure hydrogel, and the network structure hydrogel can improve the solubility of hydrophobic drugs, thereby improving the drug loading capacity of the hydrogel. The drug-loaded hydrogel can slowly and continuously release the drugs at the site of spinal cord injury for repair treatment, avoid side effects caused by excessively high local concentration, and help the repair of movement and nerve function at the injury site. The hydrogel itself can provide a structural scaffold for axon and neuron regeneration for tissue regeneration, and further improve the therapeutic effect of the hydrophobic drugs. Moreover, the preparation method of the microemulsion hydrogel is simple, raw materials are cheap and easy to obtain, and the method is suitable for large-scale production.

The invention belongs to the technical field of medicines, and relates to a 2, 4-disubstituted pyridine derivative, in particular to a compound as shown in a formula (II) and structural forms such as nitrogen oxides, isomers, solvates and pharmaceutically acceptable salts of the compound. Furthermore, the invention also discloses a preparation method and pharmaceutical application of the 2, 4-disubstituted pyridine derivative, and the 2, 4-disubstituted pyridine derivative can be used as a PI3Kalpha agonist and is used for preventing or treating PI3Kalpha activation-related body disorder and the like, including but not limited to heart protection of ischemia reperfusion injury, neuron regrowth after nerve injury and the like.

This disclosure provides novel and innovative compositions of neuronal regeneration-promoting cells (NRPCs), methods for generating NRPCs, and methods for treating subjects having damaged nerve cells using NRPCs. In one embodiment, the NRPCs are derived from tonsil-derived mesenchymal stem cells and express CD26, CD106, CD112, CD121a, and CD141, where CD121a has an expression level of approximately 30% or higher, and this expression level is measured immediately after thawing the NRPCs from a thawed state. Furthermore, the NRPCs are configured to promote axon formation on neuronal cells.